According to IQ4I analysis, the contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence & prevalence of chronic diseases and demand for diagnostic & interventional radiology procedures, increase in aging population, Expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement.
The contrast agents/Media global market is segmented by molecule, modality, applications, route of administration, imaging, end-users and geography. Based on the molecule type, the market is segmented into Iodine based [Ionic -Monomer), Non-Ionic (Monomer and Dimer)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], Microbubble based contrast agent and others which include Barium, and iron. Among the molecules, the iodine-based contrast agents market held the largest market revenue in 2020. The Microbubble segment is expected to grow rapidly at high teen CAGR from 2020 to 2027 due to the increasing number of clinical trials for the expansion of disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic. Non-Ionic Iodine-based contrast agents market accounted for the largest share of 69.5% in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027 due to the advantages of Non-ionic iodine contrast agents over ionic based contrast agents because of lower osmolality, they are better tolerated and they appear to have less toxicity. Non-Ionic Iodine-based contrasts are further segmented by their chemical structure into monomer and dimer. Monomer market accounted for the largest share in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027 as they safer and tolerable when compared to ionic contrast agents and low osmolar agents do not dissociate into a particle in solution and helps in reducing the neurotoxicity. Gadolinium-based contrast agents are segmented into linear and macrocyclic based on the chemical structures. Among them, the Macrocyclic based contrast agents market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the advantages of macrocyclic over linear based contrast agents in terms of stability and less toxicity. Macrocyclic-based contrast agent further segmented into ionic and non-ionic. Among these, Non-Ionic accounted for the largest revenue in 2020. The ionic segment is growing at high single digit CAGR from 2020 to 2027.
The contrast agents market by modality is segmented into X-ray/CT, MRI and Ultrasound. X-Ray/CT market held the largest market revenue in 2020 and is expected grow at mid single digit CAGR from 2020 to 2027. The ultrasound segment is growing rapidly at high teen CAGR from 2020 to 2027 due to increased use in diagnostic procedures especially echocardiography, focal liver lesions and ultrasonography of the urinary tract.
The contrast agents market by applications is segmented into cardiovascular, cancer, gastrointestinal, musculoskeletal, neurology, nephrology, obstetrics & gynecology, urology and others which include the neck, liver and salivary gland imaging. The cardiovascular market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the increasing incidence and prevalence of cardiovascular diseases such as coronary heart disease, heart attack, atherosclerosis & others, increase utilization of contrast agents in coronary angiography procedures and approval contrast agents for cardiovascular indications. Cancer is the fastest-growing segment at high single digit CAGR from 2020 to 2027 due to increasing incidence and prevalence of various types of cancer, expansion of indication of contrast agents for cancer and emerging approach of development of targeted nanoparticle-based contrast agents for cancer. According to IQ4I analysis, the Contrast Agents market by route of administration is segmented into intravascular, oral, rectal and others which include (intrathecal and body cavity). Intravascular accounted for the largest share in 2020 and is the fastest-growing segment with a projected high single digit CAGR from 2020 to 2027.
The contrast Agents market by imaging is segmented into diagnostic and interventional imaging. The diagnostic imaging market held the largest market revenue in 2020 and is expected to grow at high single digit CAGR from 2020 to 2027. Interventional imaging is the fastest-growing segment with low teen CAGR from 2020 to 2027 due to an increase in image guided procedures and an increase in the aging population who usually opt for minimally invasive procedures.
Based on end-user, contrast agents market is segmented into hospitals, diagnostic & ambulatory surgical centers and others which include academic and research institutes. The hospitals market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the rise in demand for the diagnosis and interventional treatment of diseases using CT or X-Ray, MRI and ultrasound imaging procedures. Diagnostic & Ambulatory surgical centers are the fastest-growing segment with a projected high single digit CAGR from 2020 to 2027 due to an increase in the number of diagnostic procedures related to musculoskeletal (arthroscopy, imaging of spine), gastrointestinal (imaging of the abdomen, GI tract) and obstetrics & gynecology (hysterosalpingography).
Based on the region, the contrast agent global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K and Rest of Europe), Asia-Pacific (Japan, China, South Korea, and Rest of APAC) and Rest of the world (Turkey, Brazil, Rest of Latin America and Middle East & Africa). North America accounted for the largest and fastest-growing region with revenue in 2020 by growing at high single digit CAGR from 2020 to 2027. The factors such as increasing incidence and prevalence of the chronic disease, increase in aging population, approval of contrast agents for various indications, expanding indications of contrast agents, increasing number of contrast mediated diagnostic and interventional procedures, approach for the development of novel contrast agents by the startup companies and favorable reimbursement will drive North America contrast agent market.
The contrast agents global market is consolidated. The top five players occupy major share of the market share and the remaining XX% of the market is occupied by other players. All the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players of the contrast agents market are GE Company (GE Healthcare) (U.S.), Bayer Group (Germany), Guerbet (France), Taejoon Pharm Co. Ltd., (South Korea), Beijing Beilu Pharmaceuticals Company Limited (China), Bracco Group (Italy), Fujifilm Holding Corporation (Japan), Sanochemia Pharmazeutika AG (Austria), Dongkook Lifescience (Korea), Lantheus medical imaging (U.S.) and Fujipharma Co. Ltd (Japan).
Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic or interventional imaging investigation are known as contrast agents. These substances are administered directly through veins, arteries, joints, rectally, body cavity or consumed orally. X-ray and computed tomography (CT) imaging exams make use of iodinated and barium-based contrast agents, whereas, Gadolinium-based contrast agents are preferred in MRI (Magnetic Resonance Imaging). These substances improve the reporting or accuracy of how internal structures of the body are working and any associated abnormalities. Ultrasound scans make use of special contrast agents called microbubbles which strongly interact with the ultrasound beam and enhance the details of the heart, liver and kidney.
According to IQ4I analysis, the contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence & prevalence of chronic diseases and demand for diagnostic & interventional radiology procedures, increase in aging population, Expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement.
The contrast agents/Media global market is segmented by molecule, modality, applications, route of administration, imaging, end-users and geography. Based on the molecule type, the market is segmented into Iodine based [Ionic -Monomer), Non-Ionic (Monomer and Dimer)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], Microbubble based contrast agent and others which include Barium, and iron. Among the molecules, the iodine-based contrast agents market held the largest market revenue in 2020. The Microbubble segment is expected to grow rapidly at high teen CAGR from 2020 to 2027 due to the increasing number of clinical trials for the expansion of disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic. Non-Ionic Iodine-based contrast agents market accounted for the largest share of 69.5% in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027 due to the advantages of Non-ionic iodine contrast agents over ionic based contrast agents because of lower osmolality, they are better tolerated and they appear to have less toxicity. Non-Ionic Iodine-based contrasts are further segmented by their chemical structure into monomer and dimer. Monomer market accounted for the largest share in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027 as they safer and tolerable when compared to ionic contrast agents and low osmolar agents do not dissociate into a particle in solution and helps in reducing the neurotoxicity. Gadolinium-based contrast agents are segmented into linear and macrocyclic based on the chemical structures. Among them, the Macrocyclic based contrast agents market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the advantages of macrocyclic over linear based contrast agents in terms of stability and less toxicity. Macrocyclic-based contrast agent further segmented into ionic and non-ionic. Among these, Non-Ionic accounted for the largest revenue in 2020. The ionic segment is growing at high single digit CAGR from 2020 to 2027.
The contrast agents market by modality is segmented into X-ray/CT, MRI and Ultrasound. X-Ray/CT market held the largest market revenue in 2020 and is expected grow at mid single digit CAGR from 2020 to 2027. The ultrasound segment is growing rapidly at high teen CAGR from 2020 to 2027 due to increased use in diagnostic procedures especially echocardiography, focal liver lesions and ultrasonography of the urinary tract.
The contrast agents market by applications is segmented into cardiovascular, cancer, gastrointestinal, musculoskeletal, neurology, nephrology, obstetrics & gynecology, urology and others which include the neck, liver and salivary gland imaging. The cardiovascular market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the increasing incidence and prevalence of cardiovascular diseases such as coronary heart disease, heart attack, atherosclerosis & others, increase utilization of contrast agents in coronary angiography procedures and approval contrast agents for cardiovascular indications. Cancer is the fastest-growing segment at high single digit CAGR from 2020 to 2027 due to increasing incidence and prevalence of various types of cancer, expansion of indication of contrast agents for cancer and emerging approach of development of targeted nanoparticle-based contrast agents for cancer. According to IQ4I analysis, the Contrast Agents market by route of administration is segmented into intravascular, oral, rectal and others which include (intrathecal and body cavity). Intravascular accounted for the largest share in 2020 and is the fastest-growing segment with a projected high single digit CAGR from 2020 to 2027.
The contrast Agents market by imaging is segmented into diagnostic and interventional imaging. The diagnostic imaging market held the largest market revenue in 2020 and is expected to grow at high single digit CAGR from 2020 to 2027. Interventional imaging is the fastest-growing segment with low teen CAGR from 2020 to 2027 due to an increase in image guided procedures and an increase in the aging population who usually opt for minimally invasive procedures.
Based on end-user, contrast agents market is segmented into hospitals, diagnostic & ambulatory surgical centers and others which include academic and research institutes. The hospitals market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the rise in demand for the diagnosis and interventional treatment of diseases using CT or X-Ray, MRI and ultrasound imaging procedures. Diagnostic & Ambulatory surgical centers are the fastest-growing segment with a projected high single digit CAGR from 2020 to 2027 due to an increase in the number of diagnostic procedures related to musculoskeletal (arthroscopy, imaging of spine), gastrointestinal (imaging of the abdomen, GI tract) and obstetrics & gynecology (hysterosalpingography).
Based on the region, the contrast agent global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K and Rest of Europe), Asia-Pacific (Japan, China, South Korea, and Rest of APAC) and Rest of the world (Turkey, Brazil, Rest of Latin America and Middle East & Africa). North America accounted for the largest and fastest-growing region with revenue in 2020 by growing at high single digit CAGR from 2020 to 2027. The factors such as increasing incidence and prevalence of the chronic disease, increase in aging population, approval of contrast agents for various indications, expanding indications of contrast agents, increasing number of contrast mediated diagnostic and interventional procedures, approach for the development of novel contrast agents by the startup companies and favorable reimbursement will drive North America contrast agent market.
The contrast agents global market is consolidated. The top five players occupy major share of the market share and the remaining XX% of the market is occupied by other players. All the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players of the contrast agents market are GE Company (GE Healthcare) (U.S.), Bayer Group (Germany), Guerbet (France), Taejoon Pharm Co. Ltd., (South Korea), Beijing Beilu Pharmaceuticals Company Limited (China), Bracco Group (Italy), Fujifilm Holding Corporation (Japan), Sanochemia Pharmazeutika AG (Austria), Dongkook Lifescience (Korea), Lantheus medical imaging (U.S.) and Fujipharma Co. Ltd (Japan).
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 REPORT SCOPE
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET CRACKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
2.6.7.1 Procedural volume assumptions
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing demand for diagnostic and interventional radiology procedures
3.3.1.2 Increase in aging population
3.3.1.3 Expansion in indications of contrast media
3.3.1.4 Increasing research activities towards the development of novel contrast agents
3.3.1.5 The growth of medical imaging technologies in emerging markets
3.3.1.6 Favorable reimbursement
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Side effect associated with contrast agents
3.3.2.2 Shortage of radiologists
3.3.2.3 Availability of alternative products
3.3.2.4 Stringent regulations for contrast agents
3.4 REGULATORY GUIDELINES
3.4.1 UNITED STATES
3.4.2 EUROPE
3.4.3 CHINA
3.4.4 JAPAN
3.4.5 SOUTH KOREA
3.4.6 INDIA
3.5 REIMBURSEMENT SCENARIO
3.5.1 REIMBURSEMENT TABLE
3.6 TECHNOLOGICAL ADVANCEMENTS
3.6.1 INTRODUCTION
3.6.2 ADVANCEMENTS IN COMPUTED TOMOGRAPHY TECHNOLOGY
3.6.3 NANOPARTICLES BASED CONTRAST AGENTS
3.6.4 MULTIMODAL CONTRAST AGENTS
3.6.5 MANGANESE-BASED MRI CONTRAST AGENTS
3.6.6 APPLICATION OF AI IN CONTRAST IMAGING
3.6.7 BISMUTH BASED CONTRAST AGENTS
3.6.8 SUPRAMOLECULAR MACROMOLECULAR ORGANIC RADICAL CONTRAST AGENT
3.6.9 XENON MAGNETIC RESONANCE IMAGING
3.6.10 UPCOMING TECHNOLOGIES/PRODUCTS
3.7 IMPACT OF COVID-19 ON IMAGING PROCEDURES
3.8 CLINICAL TRIALS
3.9 SUPPLY CHAIN ANALYSIS
3.10 PORTER’S FIVE FORCE ANALYSIS
3.10.1 THREAT OF NEW ENTRANTS
3.10.2 THREAT OF SUBSTITUTES
3.10.3 BARGAINING POWER OF SUPPLIERS
3.10.4 BARGAINING POWER OF BUYERS
3.10.5 RIVALRY AMONG EXISTING COMPETITORS
3.11 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.11.1 GLOBAL CONTRAST AGENT GLOBAL MARKET
3.11.2 GLOBAL X-RAY/CT CONTRAST AGENTS MARKET
3.11.3 GLOBAL MRI CONTRAST AGENTS MARKET
3.11.4 GLOBAL ULTRASOUND BASED CONTRAST AGENTS MARKET
3.12 COMPUTED TOMOGRAPHY MARKET – NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
3.12.1 GLOBAL COMPUTED TOMOGRAPHY MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
3.12.2 NORTH AMERICA COMPUTED TOMOGRAPHY MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
3.12.3 EUROPE COMPUTED TOMOGRAPHY MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED,AND MARKET SIZE
3.12.4 APAC COMPUTED TOMOGRAPHY MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
3.12.5 ROW COMPUTED TOMOGRAPHY MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
3.13 MAGNETIC RESONANCE IMAGING MARKET-PROCEDURE VOLUME, VOLUME OF CONTRAST AGENT CONSUMED & MARKET SIZE
3.13.1 GLOBAL MAGNETIC RESONANCE IMAGING MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
3.13.2 NORTH AMERICA MAGNETIC RESONANCE IMAGING MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
3.13.3 EUROPE MAGNETIC RESONANCE IMAGING MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
3.13.4 APAC MAGNETIC RESONANCE IMAGING MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
3.13.5 ROW MAGNETIC RESONANCE IMAGING MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
4 CONTRAST AGENTS GLOBAL MARKET, BY MOLECULE
4.1 INTRODUCTION
4.2 IODINE BASED CONTRAST MEDIA
4.2.1 IODINE BASED IONIC CONTRAST MEDIA
4.2.2 IODINE BASED NON-IONIC CONTRAST MEDIA
4.2.2.1 Monomer
4.2.2.2 Dimer
4.3 GADOLINIUM-BASED CONTRAST MEDIA
4.3.1 MACROCYCLIC
4.3.1.1 Ionic
4.3.1.2 Non-Ionic
4.3.2 LINEAR
4.3.2.1 Ionic
4.3.2.2 Non-Ionic
4.4 MICROBUBBLE BASED CONTRAST MEDIA
4.5 OTHER CONTRAST MEDIA
5 CONTRAST AGENTS GLOBAL MARKET, BY MODALITY
5.1 INTRODUCTION
5.2 X-RAY/COMPUTED TOMOGRAPHY (CT)
5.3 MAGNETIC RESONANCE IMAGING (MRI)
5.4 ULTRASOUND
6 CONTRAST AGENTS GLOBAL MARKET, BY APPLICATION
6.1 INTRODUCTION
6.2 CARDIOVASCULAR
6.3 CANCER
6.4 GASTROINTESTINAL
6.5 MUSCULOSKELETAL
6.6 NEUROLOGY
6.7 NEPHROLOGY
6.8 OBSTETRICS AND GYNECOLOGY
6.9 UROLOGY
6.10 OTHERS
7 CONTRAST AGENTS GLOBAL MARKET, BY ROUTE OF ADMINISTRATION
7.1 INTRODUCTION
7.2 INTRAVASCULAR
7.3 ORAL
7.4 RECTAL
7.5 OTHERS
8 CONTRAST AGENTS GLOBAL MARKET, BY IMAGING
8.1 INTRODUCTION
8.2 DIAGNOSTIC IMAGING
8.3 INTERVENTIONAL IMAGING
9 CONTRAST AGENTS GLOBAL MARKET, BY END-USERS
9.1 INTRODUCTION
9.2 HOSPITAL
9.3 DIAGNOSTIC & AMBULATORY SURGICAL CENTERS
9.4 OTHER END-USER
10 REGIONAL ANALYSIS
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 THE U.S.
10.2.2 REST OF NORTH AMERICA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 THE U.K.
10.3.4 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 SOUTH KOREA
10.4.4 REST OF APAC
10.5 REST OF THE WORLD
10.5.1 TURKEY
10.5.2 BRAZIL
10.5.3 LATAM AND MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 APPROVALS
11.3 AGREEMENT
11.4 ACQUISITION
12 MAJOR PLAYER PROFILES
12.1 BAYER GROUP
12.1.1 OVERVIEW
12.1.2 FINANCIALS
12.1.3 PRODUCT PORTFOLIO
12.1.4 KEY DEVELOPMENTS
12.1.5 BUSINESS STRATEGY
12.1.6 SWOT ANALYSIS
12.2 BEIJING BEILU PHARMACEUTICAL CO., LTD
12.2.1 OVERVIEW
12.2.2 FINANCIALS
12.2.3 PRODUCT PORTFOLIO
12.2.4 KEY DEVELOPMENTS
12.2.5 BUSINESS STRATEGY
12.2.6 SWOT ANALYSIS
12.3 BRACCO GROUP
12.3.1 OVERVIEW
12.3.2 FINANCIALS
12.3.3 PRODUCT PORTFOLIO
12.3.4 KEY DEVELOPMENTS
12.3.5 BUSINESS STRATEGY
12.3.6 SWOT ANALYSIS
12.4 DONGKOOK LIFE SCIENCE
12.4.1 OVERVIEW
12.4.2 FINANCIALS
12.4.3 PRODUCT PORTFOLIO
12.4.4 KEY DEVELOPMENTS
12.4.5 BUSINESS STRATEGY
12.4.6 SWOT ANALYSIS
12.5 FUJIPHARMA CO LTD
12.5.1 OVERVIEW
12.5.2 FINANCIALS
12.5.3 PRODUCT PORTFOLIO
12.5.4 KEY DEVELOPMENTS
12.5.5 BUSINESS STRATEGY
12.5.6 SWOT ANALYSIS
12.6 GE COMPANY (GE HEALTHCARE)
12.6.1 OVERVIEW
12.6.2 FINANCIALS
12.6.3 PRODUCT PORTFOLIO
12.6.4 KEY DEVELOPMENTS
12.6.5 BUSINESS STRATEGY
12.6.6 SWOT ANALYSIS
12.7 GUERBET
12.7.1 OVERVIEW
12.7.2 FINANCIALS
12.7.3 PRODUCT PORTFOLIO
12.7.4 KEY DEVELOPMENTS
12.7.5 BUSINESS STRATEGY
12.7.6 SWOT ANALYSIS
12.8 LANTHEUS MEDICAL IMAGING INC.
12.8.1 OVERVIEW
12.8.2 FINANCIALS
12.8.3 PRODUCT PORTFOLIO
12.8.4 KEY DEVELOPMENTS
12.8.5 BUSINESS STRATEGY
12.8.6 SWOT ANALYSIS
12.9 SANOCHEMIA PHARMACEUTICAL AG
12.9.1 OVERVIEW
12.9.2 FINANCIALS
12.9.3 PRODUCT PORTFOLIO
12.9.4 KEY DEVELOPMENTS
12.9.5 BUSINESS STRATEGY
12.9.6 SWOT ANALYSIS
12.10 TAEJOON PHARM CO., LTD
12.10.1 OVERVIEW
12.10.2 FINANCIALS
12.10.3 PRODUCT PORTFOLIO
12.10.4 KEY DEVELOPMENTS
12.10.5 BUSINESS STRATEGY
12.10.6 SWOT ANALYSIS
*If Applicable.
Links
[1] https://www.marketresearchreports.com/countries/global[2] https://www.marketresearchreports.com/pharma-healthcare[3] https://www.marketresearchreports.com/healthcare[4] https://www.marketresearchreports.com/pharma-healthcare-technology[5] https://www.marketresearchreports.com/pharmaceutical-manufacturing[6] https://www.marketresearchreports.com/research-development-pharma-healthcare